ID | 112445 |
Author |
Horinouchi, Yuya
Tokushima University
Ikeda, Yasumasa
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Fukushima, Keijo
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Hamano, Hirofumi
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Izawa-Ishizawa, Yuki
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Takechi, Kenshi
Tokushima University
Ishizawa, Keisuke
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
|
Content Type |
Journal Article
|
Description | Renal tubulointerstitial injury, an inflammation-associated condition, is a major cause of chronic kidney disease (CKD). Levels of activated factor X (FXa), a blood coagulation factor, are increased in various inflammatory diseases. Therefore, we investigated the protective effects of an FXa inhibitor against renal tubulointerstitial injury using unilateral ureteral obstruction (UUO) mice (a renal tubulointerstitial fibrosis model) and the Food and Drug Administration Adverse Events Reporting System (FAERS) database. The renal expression levels of FX and the FXa receptors protease-activated receptor (PAR)-1 and PAR-2 were significantly higher in UUO mice than in sham-operated mice. UUO-induced tubulointerstitial fibrosis and extracellular matrix expression were suppressed in UUO mice treated with the FXa inhibitor edoxaban. Additionally, edoxaban attenuated UUO-induced macrophage infiltration and inflammatory molecule upregulation. In an analysis of the FAERS database, there were significantly fewer reports of tubulointerstitial nephritis for patients treated with FXa inhibitors than for patients not treated with inhibitors. These results suggest that FXa inhibitors exert protective effects against CKD by inhibiting tubulointerstitial fibrosis.
|
Journal Title |
Scientific Reports
|
ISSN | 20452322
|
Publisher | Springer Nature
|
Volume | 8
|
Start Page | 10858
|
Published Date | 2018-07-18
|
Remark | Supplementary Figure : srep_8_10858_s1.pdf
|
Rights | © The Author(s) 2018
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
Pharmaceutical Sciences
University Hospital
|